1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Qualitative assessment of patients with brain tumors: intraindividual comparison of 0.05-mmol/kg gadobenate and 0.1-mmol/kg gadoterate^{^a}
Diagnostic Information End Point Reader Gadobenate Preferred No Difference Gadoterate Preferred Significance (P Value)^{^b} 3-Reader Agreement κ Value (% Agreement)
Global diagnostic preference 1 14 (14.6%) 75 (78.1%) 7 (7.3%) .13 0.505 (63.4%)
2 18 (19.2%) 56 (59.6%) 20 (21.3%) .75
3 15 (15.8%) 63 (66.3%) 17 (17.9%) .73
Lesion-border delineation 1 11 (11.4%) 76 (79.2%) 9 (9.4%) .824 0.493 (71.0%)
2 12 (12.8%) 66 (70.2%) 16 (17.0%) .46
3 8 (8.4%) 77 (81.1%) 10 (10.5%) .815
Definition of disease extent 1 6 (6.3%) 84 (87.5%) 6 (6.3%) 1.00 0.443 (79.6%)
2 5 (5.3%) 83 (88.3%) 6 (6.4%) 1.00
3 7 (7.4%) 80 (84.2%) 8 (8.4%) 1.00
Visualization of lesion internal morphology 1 4 (4.2%) 88 (91.7%) 4 (4.2%) 1.00 0.459 (84.9%)
2 3 (3.2%) 87 (92.6%) 4 (4.3%) 1.00
3 5 (5.3%) 82 (86.3%) 8 (8.4%) .581
Lesion contrast enhancement 1 10 (10.4%) 77 (80.2%) 9 (9.4%) 1.00 0.531 (66.7%)
2 18 (19.2%) 56 (59.6%) 20 (21.3%) .75
3 14 (14.7%) 64 (67.4%) 17 (17.9%) .598
↵a Comparisons based on the number of patients with both postdose T1SE images assessed and technically adequate: n = 96 for reader 1, n = 94 for reader 2, and n = 95 for reader 3. Numbers in parentheses, except where noted, represent proportions of patients.
↵b Wilcoxon signed rank test.